Indication
Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Free account required
Ask Prognia AI about Camcevi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.